Trade Dyadic International, Inc. - DYAI CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.0239
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022262 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02226%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00004 %($0.01)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00004%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 10
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022262 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00004 %
  ($0.01)

Key Stats

• Prev. Close: 0.4648
• Open: 0.4344
• 1-Year Change: -59.66%
• Day's Range: 0.4344 - 0.4744

Trade Dyadic International, Inc. - DYAI

About Dyadic International, Inc.

Dyadic International, Inc. is a biotechnology platform company. The Company is focused on developing C1 platform for use in human and animal pharmaceutical applications across the world. The C1 platform technology is based on the Myceliopthora thermophila fungus, which the Company named it as C1. The C1 gene expression platform is used in the discovery, development and manufacturing of biologic medicines and vaccines. The C1 technology is a fungal expression system for gene discovery, development, and production of enzymes and other proteins. The C1 technology is commercially available solutions to uptake genes and develop industrial processes to produce volumes of enzymes and other protein products. The Company is also working on COVID-19 related vaccine and antibody opportunities, including COVID-19 vaccine candidate, DYAI-100.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Dyadic International, Inc. revenues increased 66% to $2.1M. Net loss increased 20% to $8.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and Development - Balancing val increase from $2M to $5.8M (expense), General and administration increase of 61% to $3.8M (expense).

Equity composition

Common Stock $.001 Par, 12/10, 100M auth., 31,138,120 issd. insiders own 6.80%.10/29/04, acquired CCP Worldwide Inc. as a reverse acquisition.01/08, Company delisted from AMEX to OTC Pink Sheets.